DER zweiwöchentliche Market Access Podcast von MArS Market Access & Pricing Strategy GmbH

MAP Podcast

Market Access (oder alternativ „Kostenerstattung“) im Gesundheitswesen ist DIE Schlüsselkompetenz, um mit einem neuen Medikament, einem Medizinprodukt oder einer digitalen Gesundheitsanwendung kommerziell erfolgreich zu sein. Da der Marktzugang jedoch ein komplexer Bereich ist, der verschiedene Disziplinen umfasst und sich ständig verändert, kann es schwierig sein, mit den verschiedenen Entwicklungen in diesem Bereich in der Welt Schritt zu halten.

MAP ist DER zweiwöchentliche Marktet Access Podcast von MArS Market Access & Pricing Strategy, Ihrem Beratungsunternehmen für das Gesundheitswesen in den deutschsprachigen Märkten, welches Sie über Market Access, Erstattung und Preisgestaltung in den D-A-CH-Ländern und weltweit auf dem Laufenden hält. Mit MAP erhalten Sie einen Überblick über die wichtigsten Market Access Steme und -Prozesse sowie über die neuesten Änderungen in der Gesetzgebung, einschließlich Stellungnahmen und Meinungen der wichtigsten Entscheidungsträger und Interessenvertreter aus verschiedenen Ländern.

Podcast verfügbar über:

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare 

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer discusses with the Canadian experts Louise Perrault and Nicole Tunstall the process for reimbursement and the specifics of Quebec. What are requirements and what might be important early steps to consider in order to plan for success. Additionally, the pricing is being considered, especially the various institutions and the way to get prices negotiated and agreed within the health care system in Canada.

 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #HTA #pharma #healthcare 

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024. Anyhow, methods and processes are not yet communicated and established as of March 2023. Furthermore, there are no opportunities for early consultation to plan clinical trials and/or EU joint HTA dossiers. The core question still remains for which endpoints and comparators data would need to be submitted and by when? What would happen if the EMA label changes last minute with an impact on joint HTA assessments. Furthermore, nobody yet knows how these results will be implemented by national payers. More established HTA systems such as France and Germany might only adopt (slightly), others might utilize the full report of the EU joint HTA and directly start with the price negotiations.

Many open questions which have been discussed between the reimbursement veteran Dr. Stefan Walzer and his guests on the podcast Priyanka Kiritharan and Chloe Sheppard. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #EU #EU-Joint-HTA #pharma #healthcare